| __timestamp | Catalyst Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 5078000000 |
| Thursday, January 1, 2015 | 8597010 | 4717000000 |
| Friday, January 1, 2016 | 7910260 | 5096000000 |
| Sunday, January 1, 2017 | 7304399 | 4986000000 |
| Monday, January 1, 2018 | 15875961 | 4214000000 |
| Tuesday, January 1, 2019 | 36881187 | 3806000000 |
| Wednesday, January 1, 2020 | 44233754 | 3671000000 |
| Friday, January 1, 2021 | 49628000 | 3528000000 |
| Saturday, January 1, 2022 | 58183000 | 3445000000 |
| Sunday, January 1, 2023 | 133710000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Catalyst Pharmaceuticals, Inc. over the past decade.
Teva, a global leader, has seen its SG&A expenses decrease by approximately 31% from 2014 to 2023, reflecting strategic cost management amidst market challenges. In contrast, Catalyst Pharmaceuticals, a smaller yet dynamic player, has experienced a staggering 2,887% increase in SG&A expenses during the same period, indicating aggressive expansion and investment in growth.
These trends highlight the contrasting strategies of established versus emerging companies in the pharmaceutical sector. As Teva focuses on efficiency, Catalyst is investing heavily in its future, setting the stage for an intriguing competitive landscape.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.